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Abstract
The use of G protein-coupled receptors fluorescent ligands is undergoing continuous expansion. In 
line with this, fluorescent agonists and antagonists of high affinity for G protein-coupled 
adenosine and P2Y receptors have been shown to be useful pharmacological probe compounds. 
Fluorescent ligands for A1R, A2AR, and A3R (adenosine receptors) and P2Y2R, P2Y4R, P2Y6R, 
and P2Y14R (nucleotide receptors) have been reported. Such ligands have been successfully 
applied to drug discovery and to GPCR characterization by flow cytometry, fluorescence 
correlation spectroscopy, fluorescence microscopy, fluorescence polarization, fluorescence 
resonance energy transfer and scanning confocal microscopy. Here we summarize recently 
reported and readily available representative fluorescent ligands of purinergic receptors. In 
addition, we pay special attention on the use of this family of fluorescent ligands revealing two 
main aspects of purinergic receptor biology, namely ligand binding and receptor oligomerization.
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1. Introduction
The purinergic neurotransmission system involves two main extracellular effectors, namely 
adenosine and adenosine 5′-triphosphate (ATP) (Burnstock, 1972). In the central nervous 
system (CNS), while adenosine acts as a neuromodulator, ATP also operates as a 
neurotransmitter. Despite the initial resistance to acceptance of ATP as a genuine 
extracellular signaling molecule, the existence of consistent physiological effects and 
specific extracellular enzymes regulating this molecule eventually supported its role as 
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neurotransmitter, and consequently the existence of a purinergic neurotransmission system 
(Burnstock, 1972). Afterwards, ATP was identified as a co-transmitter in peripheral nerves 
and subsequently as a co-transmitter with glutamate, noradrenaline, GABA, acetylcholine 
and dopamine in the CNS (Burnstock, 2004). Interestingly, extracellular ATP is quickly 
hydrolyzed into adenosine 5′-diphosphate (ADP), adenosine 5′-monophosphate (AMP) and 
adenosine plus inorganic phosphate and pyrophosphate, through the action of extracellular 
nucleotidases (ecto-NTs) (e.g. ecto-NTPDases and ecto-5′-nucleotidase) (Zimmermann, 
1996). Adenosine, which consists of a purine base (adenine) attached to the 1′ carbon atom 
of ribose, has been historically considered a retaliatory metabolite modulating a large array 
of physiological processes (Newby, 1984). Accordingly, it has been postulated that this 
purine nucleoside is a mediator of metabolic distress, thus having considerable impact on 
homeostatic cellular functioning. In addition, there is supporting information confirming the 
involvement of adenosine and ATP in the pathophysiology of the CNS, including 
neurodegenerative diseases, neuropsychiatric disorders and cancer (i.e. neurogliomas), 
which have lead to an explosion of interest related to the purinergic neurotransmission 
system.
Extracellular ATP and adenosine exert their effects via specific plasma membrane receptors. 
In 1976 purinergic receptors were first defined (Burnstock, 1976), and two years later 2 
types of purinoceptors, named P1 and P2 for adenosine and ATP/ADP, respectively, were 
proposed (Burnstock, 1978). The dual effect of adenosine on cAMP accumulation served as 
initial subclassification of adenosine receptors into Ri and Ra (Londos et al., 1980), or 
alternatively, A1 and A2 adenosine receptors (van Calker et al., 1979). Nowadays, it is well 
established that adenosine mediates its actions by activating specific P1 purinergic G 
protein-coupled receptors (GPCRs), for which four subtypes (i.e. A1R, A2AR, A2BR and 
A3R) have been identified (Table 1). These receptors have a distinguishable 
pharmacological profile, tissue distribution and effector coupling (Jacobson and Gao, 2006) 
(Table 1), and its functioning have been largely studied in the CNS (Sebastião and Ribeiro, 
2009). In 1985, P2 receptors were subdivided into P2X and P2Y subtypes on the basis of 
pharmacology (Burnstock and Kennedy, 1985). While P2X are ligand-gated ion channel 
receptors, the P2Y subtypes are GPCRs (Burnstock and Williams, 2000). Currently, eight 
subtypes of the P2Y family (i.e. P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and 
P2Y14) have been cloned and functionally characterized (Abbracchio et al., 2006). 
Receptors of the P2Y family are variously activated by an expanded list of nucleotides, 
including ATP, ADP, UTP, UDP and UDP-sugars.
The wide-spread expression of purinergic receptors, in addition to the diverse and abundant 
roles of these receptors in extracellular signaling, has lead, as commented above, to a great 
deal of interest for pharmacologists in general and for neuropharmacologists in particular. 
Indeed, the physiological and pathophysiological consequences of targeting these receptors 
with specific ligands may offer new opportunities for a purinergic-based pharmacotherapy in 
various neurological and neuropsychiatric diseases. Accordingly, this scientific interest has 
prompted a dramatic growth in the purinergic pharmacology field, in which a large number 
of ligands have been designed and synthesized. Noteworthy, an important contribution to the 
purinergic field has been the development of selective ligands labeled with fluorescent 
moieties that remain active at their receptors. Interestingly, these compounds have become 
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powerful tools to address fundamental unmet questions regarding the purinergic receptor 
biology. For instance, these novel fluorescent ligands of purinergic receptors may permit the 
visualization of ligand-receptor binding at the cell surface of living cells, or help revealing 
the existence of purinergic receptor-containing oligomers in native tissue. Accordingly, in 
the present review, we not only provide an extensive overview of the currently reported 
fluorescent ligands of purinergic receptors, but also focus on aspects of the biology of 
adenosine and P2Y receptors to characterize ligand-receptor binding and receptor 
oligomerization by means of fluorescent ligands.
2. GPCR fluorescent ligands
Fluorescent ligands were introduced in the GPCR field about forty years ago as 
pharmacological tools to visualize receptors in native conditions and thus boosting the 
spatial resolution provided by other methodologies (Melamed et al., 1976). The synthesis 
and purification of these compounds was not easy in those days and thus only accessible to a 
few researchers. Later on, in the 1990s, the chemistry of fluorescent ligands substantially 
advanced, and new high-affinity compounds with improved kinetics (i.e. slow dissociation 
rates) were synthesized (McGrath et al., 1996). Therefore, by using these ligands it was 
possible to detect receptors not only at the cell surface level but also within intracellular 
compartments, thus allowing the study of receptor endocytosis (Lutz et al., 1990). Currently, 
the use of GPCR fluorescent ligands is undergoing continuous expansion (Ciruela et al., 
2014a; Hill et al., 2014; Vernall et al., 2014). In this manner, GPCR-based fluorescent 
ligands have been successfully introduced in a vast number of techniques, such as flow 
cytometry (FCM), fluorescence correlation spectroscopy (FCS), fluorescence microscopy 
(FM), fluorescence polarization (FP), fluorescence resonance energy transfer (FRET), or 
scanning confocal microscopy (SCM) (Kozma et al., 2013), for the study of receptor 
physiology and pathophysiology at both the cellular and the subcellular level (Kuder and 
Kieć-Kononowicz, 2008). In addition, they have been implemented as screening tools in 
drug discovery (Middleton and Kellam, 2005).
The use of GPCR-selective fluorescent ligands in receptor binding studies has proved to be 
complementary, and eventually superior, to the classical radioligand-based techniques. 
Certainly, these compounds show several advantages over conventional radioisotopically-
labelled ligands, for instance avoiding the cost of scintillation detection; enhanced safety and 
reduced costs as no radioisotope use and disposal is needed; ‘real-time’ readout of the 
ligand-receptor interaction, which allow kinetic experiments; direct visualization of the 
receptor localization allowing both local binding and internalization experiments; and finally 
the possibility of miniaturization, which facilitates a more economical technology (Ciruela 
et al., 2014b). On the other hand, there are some important considerations when engineering 
a fluorescent ligand, especially considering that biological activity must be preserved. Thus, 
among other important factors to be contemplated are: selection of the type of intrinsic 
activity of the pharmacophore (i.e. agonist vs. antagonist; orthosteric vs. allosteric ligand); 
the fluorophore type based on specific photophysical properties (e.g. wavelength, quantum 
yield, fluorescence lifetime, etc.) and the linker between them, which should allow 
flexibility but maintain ligand activity. Importantly, these chemical challenges have not 
prevented the synthesis of novel highly potent and selective fluorescent ligands, and the 
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number of marketed GPCR fluorescent ligands is growing rapidly. Hence, GPCR 
fluorescent ligands might become a major component of investigation of the physiological 
and pathophysiological functions of GPCRs and consequently aid the development of new 
drugs for GPCR-based pharmacotherapies.
2.1. Adenosine receptor fluorescent ligands
The first examples of fluorescent purinergic receptor ligands were synthesized by Jacobson 
et al. in 1987 (Jacobson et al., 1987). These early compounds were synthesized from both 
xanthine and adenosine amine congeners (XAC and ADAC, respectively) (Table 2) as 
bifunctional ligands containing a fluorescent dye (i.e. fluorescein isothiocyanate, FITC and 
7-nitrobenz-2-oxa-1,3-diazol-4-yl, NBD) (Fig. 1). Indeed, the initially functionalized 
congeners were versatile adenosine receptor antagonist (C8-modified alkylxanthines, XAC) 
and agonist (N6-modified adenosines, ADAC) probes to which chemically-reactive 
fluorescent dye derivatives (Fig. 1) were coupled (Table 2) (Jacobson et al., 1987). 
Accordingly, several fluorescent antagonists (1) and agonists (3,4) showing moderate to 
high affinity for A1R in rat brain were initially synthesized (Table 1 and 2) (Jacobson et al., 
1987). Importantly, these initial compounds demonstrated the feasibility of using a tethering 
approach for adenosine receptor fluorescent ligands. In addition, conjugation to biotin 
provided an additional strategy for receptor-labeling (Jacobson, 1990), with option of using 
fluorescently-labeled avidin or streptavidin. Nearly ten years later, a series of fluorescent 
derivatives of the widely used non-selective and potent adenosine receptor agonist 5′-N-
ethylcarboxamidoadenosine (NECA) were synthesized by the insertion of dansylaminoalkyl 
moieties (Fig. 1) to the N6-position of NECA with a linear alkyl spacer of increasing length 
(from 3 to 12 carbons) (Table 2) (Macchia et al., 1998). Interestingly, a compound of this 
series with a 6-carbon spacer chain (5) allowed visualizing A1R at the level of the rat 
molecular layer of the rat cerebellar cortex by means of fluorescence microscopy (Macchia 
et al., 1998). Subsequently, with the aim of overcoming difficulties related to the short 
excitation wavelength of certain fluorophores (i.e. dansyl), new fluorescent derivatives of 
NECA containing a 4-nitro-2,1,3-benzoxadiazol-7-yl (NBD) moiety (Fig. 1) were 
synthesized (Macchia et al., 2001). A compound of these series (6) (Table 2) showed 
moderate to high affinity for the A3R and thus allowed the detection of the receptor at the 
cell surface level of Chinese hamster ovary (CHO) cells (Macchia et al., 2001). Collectively, 
these results showed the impact of the fluorescent dye and linker length on receptor 
selectivity and affinity, respectively, a phenomenon that has been object of analysis (Baker 
et al., 2010). More recently, several red-shifted fluorescent NECA derivatives without 
selectivity for adenosine receptors were synthesized (Middleton et al., 2007). In this case, 
the fluorescent moiety used was BODIPY630/650-X (Fig. 1), which showed superior 
photophysical properties when compared to previously used fluorophores. Indeed, 
compound 7 allowed visualizing ligand-receptor interactions at the cell surface of CHO cells 
expressing the A1R (Middleton et al., 2007) and A3R (Cordeaux et al., 2008). Interestingly, 
by using FCS, the membrane diffusional characteristics of these two adenosine receptors 
were investigated, and two populations of agonist-occupied receptor complexes with 
different motilities within the membrane of single living cells were identified (Cordeaux et 
al., 2008; Middleton et al., 2007). Interestingly, similar results were obtained with a similar 
red-shifted compound (8) (Table 2) that bound to the A1R (Briddon et al., 2004b), thus 
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sustaining the notion of the existence of different adenosine receptor populations at the cell 
surface of living cells. Overall, these results suggested that A1R and A3R are not 
homogeneously distributed through the plasma membrane; instead, they are located within 
different membrane microdomains (i.e. caveolae and lipid-rich regions) that may determine 
their differential motility and more importantly their signaling capabilities.
In addition to the abovementioned agonists, other adenosine receptor fluorescent ligands 
with similar intrinsic activity (i.e. agonism) were described. Indeed, by using as scaffold a 
more selective A3R agonist containing a (N)-methanocarba (bicyclo[3.1.0]hexane) ring (i.e. 
MRS3558) (Table 2) (Tchilibon et al., 2005), several nanomolar and highly selective 
fluorescent agonists for the A3R were synthesized (9, 10, 11) (Table 2) (Tosh et al., 2012, 
2010, 2009). Interestingly, the most potent fluorescent A3R agonist in the (N)-methanocarba 
series is a cyanine 5 (Cy5) derivative (11) (Table 2), which showed high selectivity for the 
A3R (Tosh et al., 2009). In addition, two functional agonists (12, 13) (Table 2) at the 
adenosine A2AR in which the fluorescent dyes Alexa488 and 532, respectively, were 
covalently attached to the A2AR agonist APEC (Table 2) were synthesized. These ligands 
were mostly used in ligand-receptor binding experiments (Brand et al., 2008; Fernandez-
Duenas et al., 2012), a topic that will be further illustrated in the following sections. Finally, 
apart from the aforesaid agonists, some adenosine receptor fluorescent antagonists were also 
engineered. For instance, a non-selective fluorescent antagonist (2) (Table 2) was 
synthesized using XAC (Table 2) and used for the visualization of A1R and A3R using FCS 
in living cells (Briddon et al., 2004a; Corriden et al., 2014). In addition, an A2AR-selective 
red fluorescent antagonist (14) (Table 2) was recently used to study receptor oligomerization 
(Fernández-Dueñas et al., 2015). Overall, a plethora of adenosine receptor fluorescent 
ligands exists, and it is noteworthy that some of them are commercially available (2, 7, 14) 
(Table 2).
2.2. P2Y receptor fluorescent ligands
Extracellular nucleotides activate G protein-coupled purinergic receptors of the P2Y family. 
Significantly, while a large array of fluorescent ligands have been described for adenosine 
receptors, only three compounds are currently reported for P2Y receptors. Specifically, 
fluorescent ligands of the P2Y2R (ATP- and UTP-activated) and P2Y4R (UTP-activated), 
P2Y6R (UDP-activated), and P2Y14R (UDP- and UDP-glucose-activated) have been 
reported. High affinity radioligands for these GPCRs are not available; thus, the P2YR 
fluorescence ligands currently fulfill a need unmet by other ligand tools. The first compound 
described (17) (Table 3) was a potent and selective P2Y6R agonist containing the 
fluorophore Alexa Fluor 488 (Fig. 1) through a spacer chain constructed by click chemistry 
(Jayasekara et al., 2013). Interestingly, compound 17 was suitable for studying ligand-
receptor binding and receptor internalization kinetics on P2Y6R-expressing 1321N1 
astrocytoma cells using FCM and FM. Thus, while additional pharmacological 
characterization was still needed (i.e. ligand-receptor binding in membranes of P2Y6R 
expressing cells), the identification of the N4-benzyloxy group as a structurally permissive 
region for the synthesis of fluorescent functionalized congeners constituted a significant step 
forward enabling further P2Y6R drug discovery (Jayasekara et al., 2013). Subsequently, 
another P2Y6R fluorescent agonist (18) (Table 3) showing similar potency at P2Y2R and 
Ciruela et al. Page 5













P2Y4R was synthesized (Jayasekara et al., 2014). Accordingly, this potent P2Y2/4/6R pan-
agonist fluorescent probe was also used for studying ligand-receptor binding in P2Y6R-
expressing 1321N1 astrocytoma cells using FCM and FM (Jayasekara et al., 2014). 
Therefore, it was proposed that compound 18 could be useful routinely for the detection of 
this subset of Gq- protein-coupled P2Y receptors (Jayasekara et al., 2014). Finally, a high-
affinity P2Y14R fluorescent compound (19) (Table 3) based on the potent and highly 
selective nonnucleotide P2Y14R antagonist PPTN (Table 2) was synthesized (Kiselev et al., 
2014). Compound 19 showed an exceptionally high affinity for the P2Y14R and allowed its 
detection and characterization by using FCM (Kiselev et al., 2014). These results illustrated 
that potency of this series of 2-naphthoic acid derivatives such as PPTN can be preserved by 
chain functionalization, leading to highly potent fluorescent antagonists for P2Y14R 
(Kiselev et al., 2014). Overall, the development of selective and potent fluorescent ligands 
for purinergic P2Y receptors is a highly important goal given the role of this receptor family 
in health and disease. Consequently, further investigation will be needed to achieve a full 
pharmacological palette of fluorescent compounds for the eight subtypes of P2YRs.
3. Uncovering the biology of G protein-coupled purinergic receptors using 
fluorescent ligands
The utility of GPCR fluorescent ligands as pharmacological tools to unravel receptor 
biology has been recently reviewed (Ciruela et al., 2014a). Indeed, the biology of G protein-
coupled purinergic receptors in general and adenosine receptors in particular has been the 
primary object of study using fluorescent ligands. Thus, the analysis of ligand-receptor 
binding, receptor internalization and receptor-receptor interactions (i.e. GPCR 
oligomerization) has largely benefited from using such compounds, which in addition have 
permitted unraveling certain mechanistic aspects unsolvable by classical experimental 
approaches. Accordingly, we will analyze here in greater detail the impact of purinergic 
receptor fluorescent ligands on two of these aspects that deserve, in our opinion, special 
attention, namely ligand-receptor binding and receptor oligomerization.
3.1. Ligand-receptor binding at the surface of living cells: FRET and beyond
The first step of any receptor-mediated signal transduction is ligand-receptor binding. This 
phenomenon has been classically studied by means of radioligand binding experiments in 
which the receptor is challenged with a radioisotope-labelled ligand, and the bound fraction 
is collected and detected using various techniques, such as filtration combined with 
radioactivity counting, scintillation proximity analysis and autoradiography (Bylund and 
Toews, 1993). While these assays are extremely sensitive they present several drawbacks, 
which have been briefly outlined before. Accordingly, there is a growing need to switch 
from radioactivity to fluorescence ligand binding assays, not only for safety reasons but also 
for experimental purposes. Indeed, the use of GPCR fluorescent ligand binding assays 
enables the real-time visualization and quantification of ligand-receptor interactions, thus 
allowing fine kinetic monitoring of this essential process for receptor biology. Interestingly, 
most of the purinergic receptor fluorescent ligands used for binding assays in intact cells are 
actually antagonists, as they do not promote GPCR internalization; conversely, the use of 
fluorescent agonists are thus useful in the study of receptor internalization. For example, a 
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fluorescent agonist of the A2AR was used in FM to follow receptor internalization (Brand et 
al., 2008). The internalization of a fluorescently labelled agonist with high affinity for the 
P2Y6R was determined in astrocytoma cells expressing the P2Y6R (Jayasekara et al., 2013).
Two basic methods were initially developed to perform ligand-receptor binding experiments 
using fluorescent compounds. First, the binding of the corresponding fluorescent ligand to a 
receptor of interest was assessed and monitored either by measuring fluorescence intensity 
or FP in membrane preparations of living cells upon binding conditions. Indeed, adenosine 
receptor fluorescent ligands in binding experiments were early described for the A2AR using 
a derivative of APEC (an amine functionalized A2AR-selective agonist) in striatal bovine 
membranes (McCabe et al., 1992). In addition, an A2AR fluorescent antagonist suitable for 
FP (15) (Table 2) allowed the easy determination of the association and dissociation 
parameters, thus providing an accurate estimation of the ligand affinity (Kecskés et al., 
2010). Interestingly, the acquired data highly correlated with that obtained from radioligand 
binding experiments, thus supporting the notion that adenosine receptor fluorescent ligands 
are comparable to the classical radioligands in binding assays. The second method 
developed consisted of assessing and monitoring the binding of fluorescent ligands to intact 
living cells expressing the receptor of interest either by FCM or FCS. In such way, a new 
fluorophore-conjugated A3R antagonist (16) (Table 2) was synthesized and used for cell-
based applications. This compound clearly labelled the A3R at the plasma membrane of 
CHO cells expressing the receptor and by means of FCM a very high specific-to-nonspecific 
binding ratio was obtained (Kozma et al., 2012). Interestingly, by using this last approach an 
equilibrium binding constant comparable to that calculated from kinetic radioligand 
experiments in membranes was observed (Kozma et al., 2012). Another adenosine receptor 
fluorescent ligand used in FCM was compound 12 (Table 2), which consisted of an Alexa 
Fluor 488-conjugated A2AR agonist. This same ligand was also used in the study of ligand-
A2AR binding modulation by antiparkinsonian D2R agonists (Fernandez-Duenas et al., 
2013). Finally, the remarkable implementation of a high-content screening assay in living 
cells using compound 2 (Table 2) and a confocal imaging plate reader was reported 
(Stoddart et al., 2012). This methodology allowed the determination of the binding affinities 
of A1R and A3R ligands and also demonstrated that adenosine fluorescent ligands can be 
used in high-throughput screening (HTS) using living cells with enough sensitivity (Stoddart 
et al., 2012).
A significant advance in the use of GPCR fluorescent ligands in ligand-receptor binding 
studies consisted of the incorporation of these compounds into RET-based technologies, 
either as donor or as acceptor chromophores engaging fluorescence-RET (FRET) processes 
with RET-compatible tagged receptors (Fig. 2). In brief, FRET assays are based on the close 
proximity (<10 nm) established between donor and acceptor chromophores labelling both 
the ligand bound and the receptor, which upon ligand binding allows the energy transfer 
(Fig. 2A). Interestingly, we recently reported the use of a N-terminally cyan fluorescence 
protein (CFP)-tagged A2AR (i.e. A2ARCFP) in combination with compound 13, which 
allowed the dynamic evaluation of ligand-receptor binding in single living cells and in a 
real-time mode (Fernandez-Duenas et al., 2012). Hence, we used the elicited FRET signal 
between A2ARCFP (i.e. donor) and compound 13 (i.e. acceptor) as readout for the ligand-
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receptor binding in living cells (Fig. 2B). Accordingly, by using this FRET-based ligand-
receptor binding approach we were able to demonstrate the existence of an allosteric 
modulation of the A2AR by the dopamine D2 receptor (D2R), which was A2AR/D2R 
oligomer-dependent (Fernandez-Duenas et al., 2012). Indeed, a negative allosteric effect of 
the D2R agonist quinpirole on A2AR ligand binding and activation was observed 
(Fernandez-Duenas et al., 2012). Therefore, D2R agonists could be considered oligomer-
dependent negative allosteric modulators (NAMs) of the A2AR. In addition, by using this 
FRET-based ligand-receptor binding approach, we evaluated the A2AR NAM activity of 
different D2R agonists (i.e. pramipexole, rotigotine and apomorphine) currently used in 
clinics as antiparkinsonian agents (Fernandez-Duenas et al., 2013). Interestingly, a 
differential D2R-mediated negative allosteric modulation with apomorphine being the best 
antiparkinsonian drug attenuating A2AR agonist binding was confirmed (Fernandez-Duenas 
et al., 2013). Overall, the number of approaches using purinergic receptor fluorescent 
ligands is continuously growing, and these go from the easy primary detection of receptors 
by FCM, FCS, FM and FP to the study of the ligand-receptor interaction dynamics by means 
of real-time FRET-based approaches.
3.2. Fluorescent ligands for the study of purinergic receptor oligomerization
One exciting application of fluorescent ligands when studying GPCR biology consists of 
visualizing receptor oligomers. Such oligomers are thought to display distinct 
pharmacological properties from the monomers. Thus, any tools for distinguishing 
heteromers, homomers and monomers of GPCRs will be valuable. In such way, several 
experimental approaches using fluorescent ligands have been designed to study purinergic 
receptor oligomerization. A basic approach consists of measuring the impact of receptor 
oligomerization on the thermodynamics of fluorescent ligand-receptor binding in a real-time 
mode. In such way, A1R/A3R oligomerization was assessed by monitoring the dissociation 
kinetics of a fluorescent agonist (7) from the A1R and/or A3R expressed in CHO cells. 
Interestingly, the data obtained shed some light about the cooperative interactions taking 
place among protomers within the oligomer (May et al., 2011, 2010). Thus, these studies 
provided evidence for an allosteric modulation occurring between orthosteric binding sites 
of the adenosine receptors across their homodimeric interface, which supported the spatial 
and temporal specificity of drug action. A more sophisticated experimental approach 
consists of using FRET compatible fluorescent ligand pairs tagging the different receptors 
within the oligomer (Fig. 2C). Therefore, if two putative protomers are in close proximity 
(<10 nm), the binding of the fluorescent ligands to their binding sites may engage a FRET 
process (Fig. 2C) (Gandia et al., 2008). Interestingly, several studies have taken advantage 
of the abovementioned approach, and have demonstrated the existence of GPCR oligomers 
in heterologous expression systems and, more importantly, in native tissue. Importantly, 
fluorescent ligands are especially valuable to reveal GPCRs in native conditions, since 
physiologically expressed unmodified receptors can be readily recognized by properly-
designed selective fluorescent ligands. In such way, by means of this latter strategy we 
recently studied the well-known receptor-receptor interaction between A2AR and D2R 
occurring at the level of the striatum, a region of major interest in certain pathologies like 
Parkinson's disease (Fernández-Dueñas et al., 2015). Of note, although A2AR-D2R 
oligomerization was postulated quite a long time ago based on receptor binding in model 
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systems (Ferre et al., 1997; Fuxe et al., 1998; Torvinen et al., 2002), evidence for the 
existence of A2AR/D2R oligomers in native tissue was indirect. For instance, these receptors 
were able to co-immunoprecipitate in rat striatum homogenates, and also co-distribute 
within striatal neurons (Cabello et al., 2009). In addition, a potential direct receptor-receptor 
interaction between A2AR and D2R was suggested in view of the proximity ligation assay 
results shown in mouse and monkey brains (Bonaventura et al., 2014; Trifilieff et al., 2011). 
However, the final proof of the close A2AR-D2R proximity (<10 nm) or oligomerization was 
provided by means of time resolved-FRET (TR-FRET) experiments using specific A2AR 
and D2R fluorescent ligands (Fernández-Dueñas et al., 2015). In brief, after validating 
previous results by means of immunoelectron microscopy and proximity ligation assays, we 
applied a TR-FRET-based approach using a selective A2AR fluorescent antagonist (14) in 
combination with a D2R antagonist (N-(p-aminophenthyl)spiperone) labelled with Lumi4-
Tb. Importantly, the use of antagonists targeting the protomers within the oligomer may 
provide a higher range of detection signal to that obtained using agonist pairs, as previously 
reported (Albizu et al., 2010). Indeed, when a GPCR oligomer is challenged with two TR-
FRET-compatible fluorescent agonists some negative cooperative binding may appear, 
which may result in a lower TR-FRET signal (Albizu et al., 2010). However, when a 
functional output of GPCR oligomerization is needed to assess the existence of receptor-
receptor cooperativity phenomena, two TR-FRET-compatible fluorescent agonists are 
recommended (Durroux, 2005). The latter approach using TR-FRET compatible ligands was 
remarkable in the respect that one of the ligands was labelled with a lanthanide (i.e. terbium) 
as a donor in the TR-FRET process, which presents important advantages with respect to 
classical FRET paradigms. First, the long-lived emission fluorescence of lanthanides allows 
the temporal separation of excitation and detection events of the energy transfer (Bazin et 
al., 2001; Mathis, 1995). And second, the signal-to-noise ratio is extremely high, since the 
bleed-through of lanthanide emission into the acceptor wavelength (i.e. dy647) is negligible 
(Fig. 1) (Bazin et al., 2002; Terrillon et al., 2003). Overall, the engagement of a TR-FRET 
process between fluorescent ligands may represent a definitive tool to demonstrate receptor 
oligomerization in native conditions. However, as commented above, other approaches are 
possible using fluorescent ligands. In such way, a fluorescent ligand directed to a specific 
receptor can elicit a FRET process with a fluorescent-labelled antibody directed to the other 
protomer within the oligomer (Fig. 2C). This strategy was successfully applied to 
demonstrate the existence of D2R-ghrelin GHS-R1a receptor oligomerization (Kern et al., 
2012). However, the use of antibodies might involve some drawbacks: i) the size of 
antibodies, which may hinder proper labelling of both receptors due to steric 
incompatibilities, ii) the fact that most GPCR antibodies are directed to intracellular 
domains, thus requiring permeabilization processes that disrupt the plasma membrane and 
alter native conditions. In addition, when using antibodies, the FRET process is indeed less 
probable depending on the accessibility of the epitope or the orientation of the fluorophores. 
On the other hand, it may be considered, as commented above, that selecting an agonist 
instead of an antagonist can diminish the FRET signal, since although no cooperativity may 
exist with the antibody, receptor agonist-mediated activation may lead to possible 
internalization, thus hindering binding equilibrium between the ligand and the antibody. In 
conclusion, GPCR fluorescent ligands in general and purinergic receptor fluorescent ligands 
in particular have recently emerged as powerful tools to ascertain receptor oligomerization 
Ciruela et al. Page 9













in native conditions. Needless to say, especially when thinking of first characterizing new 
receptor-receptor interactions or screening specific oligomer-based drugs in a 
straightforward manner, i.e. in heterologous systems, the combination of fluorescent ligands 
with fluorescent-tagged receptors may represent an advantage that may also permit 
developing HTS systems. In such way, it was recently described a heterodimeric binding 
assay, as a proof of concept to screen for oligomer selective ligands (Hounsou et al., 2014). 
Interestingly, by using this assay it was possible to discriminate between the fluorescent 
ligand-receptor binding to heterodimers vs. homodimers, thus conferring this kind of 
approach the ability for identifying ligands that exhibit selectivity for heterodimers. This 
fact, as commented previously, may facilitate the search for new drugs for treating such 
pathologies (i.e. Parkinson's disease) in which an inbalance occurs between distinct GPCRs 
forming an oligomer (i.e. A2AR-D2R). Accordingly, this approach might become a useful 
tool for the characterization of another already described purinergic receptor-containing 
oligomer, namely the adenosine A1 and the P2Y1 receptor-receptor interaction described 
both in heterologously transfected cells and in rat brain tissues (for review see (Nakata et al., 
2005)), thus new FRET compatible fluorescent ligands for this pair of purinergic receptors 
will be needed.
5. Concluding remarks
Since the discovery of the purinergic neurotransmission system by Burnstock in the early 
seventies, characterizing purinergic receptors has constituted a major goal for 
neuropharmacologists. Hence, adenosine and P2Y receptors are abundantly expressed 
through the organism, and they therefore represent relevant targets in a number of 
pathologies in which the functioning of these receptors has been shown to be altered. The 
development of fluorescent ligands directed to purinergic receptors has signified an 
important step, not only to achieve the former objectives, but also in modern GPCR 
pharmacology. Thus, the number of available GPCR fluorescent ligands is growing rapidly, 
and purinergic receptors fluorescent ligands have somehow led the progress of this field. 
Importantly, the synthesis of fluorescent ligands has permitted overcoming technical 
obstacles found in classical approaches (i.e. radioactivity), thus more detailed knowledge of 
receptors biology (i.e. ligand binding, receptor oligomerization) may be fulfilled in the near 
future. These advances are expected to be readily translated into clinical diagnostics and in 
facilitating the development of novel drugs for the management of GPCR-related 
pathologies.
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• Fluorescent ligands propel G protein-coupled purinergic receptor pharmacology.
• Dynamic FRET-based ligand-adenosine receptor binding at the surface of living 
cells.
• Purinergic fluorescent ligands allow visualization of adenosine receptor-
containing oligomers in native tissue.
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Fig. 1. Structures of fluorophores used to tag purinergic receptor ligands
Abbreviations: FITC: fluorescein isothiocyanate; NBD: 7-nitrobenzofurazan-4-yl;
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Fig. 2. FRET-based purinergic receptor ligand binding assay in living cells
(A) Schematic representation of FRET between a fluorescent ligand (i.e. MRS5424) and the 
corresponding fluorescently tagged adenosine receptor (i.e. A2ARCFP). (B) Single-cell time-
resolved changes in receptor-ligand FRET signal. The recording shows the changes in the 
F554/F480 ratio upon rapid superfusion of the fluorescent ligand. Adapted from (Fernandez-
Duenas et al., 2012). (C) Endogenous receptor oligomers (i.e. D2R/A2AR) in native tissue 
can be readily detected by TR-FRET compatible specific fluorescent ligands (i.e. 
NAPSLumio4Tb and SCH442416dy647), which upon binding to their respective receptors (i.e. 
D2R and A2AR, respectively) within the oligomer can engage in a FRET process. Adapted 
from (Fernández-Dueñas et al., 2015). (D) Representative example of D2R/A2AR oligomer 
detection in membrane preparations from rat striatum incubated with NAPSLumi4Tb plus 
SCH442416dy647. The corresponding TR-FRET signal (1st column, red) is significantly 
higher than that observed in the presence of an excess of unlabelled NAPS or SCH442416. 
Adapted from (Fernández-Dueñas et al., 2015).
Ciruela et al. Page 17

























Ciruela et al. Page 18
Table 1
Adenosine receptors and representative fluorescent ligands used to label these receptors





• Activates: PLC, AC
Vasoconstriction (Murray and Churchill, 1984); 
hypothermia and sedation (Anderson et al., 1994); 
analgesia (Yamamoto et al., 2003); neurotransmitter 
release (De Lorenzo et al., 2004; Scholz and Miller, 1992); 
chemotaxis (Schnurr et al., 2004); neuroprotection 









• Activates: AC*, PLC
• Inhibits: Ca2+ channels
Platelet aggregation inhibition (Varani et al., 2000); 
vasodilation (Carroll et al., 2006); neurotransmitter release 
(Popoli et al., 1995); regulation of sensorimotor integration 
in basal ganglia (Nagel et al., 2003); sleep promotion 









•Activates: AC*, PLC Vasodilation (Kemp and Cocks, 1999); vasoconstriction 
(Donoso et al., 2005); cytokine production (Zhong et al., 
2004); inhibition of cell proliferation (Dubey et al., 2005);
2
7
A3 Gi/o* • Inhibits: AC*
• Activates: PLC
Mast cell activation (Zhong et al., 2003); preconditioning 
(Das et al., 2005);coronary vasodilation (Hinschen et al., 
2003); regulation of intraocular pressure (Avila et al., 









Main mechanism of coupling.
¥
AC, adenylyl cyclase; PLC, phospholipase C; PLA2, phospholipase A2; PLD, phospholipase D; GIRKs, G protein-dependent inwardly rectifying 
K+ channels.
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Table 2
Structures of representative fluorescent ligands used to label adenosine receptors
The conjugates shown are structurally divided into three moieties following pharmacological, covalent linking 
and fluorescent properties. See Fig. 1 for structures of fluorophores and Table 1 for references.
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Abbreviations: ADAC: adenosine amine congener; AF Alexa Fluor; APEC: 2-[(2-aminoethylamino)carbonylethyl-phenylethylamino]-5′-
ethylcarboxamidoadenosine; CGS15943: 9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine; I.A.: intrinsic activity; MRS3558:(1′S,
2′R,3′S,4′R,5′S)-4-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)-2,3- dihydroxy-N-methylbicyclo [3.1.0] hexane-1-carboxamide; NECA: 5′-
N-ethylcarboxamidoadenosine; SCH442416: 2-(2-furanyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-
amine; XAC: xanthine amine congener;
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Table 3
Structures of fluorescent ligands used to label P2Y receptors
The conjugates shown are structurally divided into three moieties following pharmacological, covalent linking 
and fluorescent properties. See Fig. 1 for structures of fluorophores and Table 1 for references.
Abbreviations: CDP: Cytidine 5′-diphosphate; MRS2964: N4-benzyloxy-CDP; MRS4062: N4-phenylpropoxycytidine-5′-O-triphosphate; PPTN: 4-
(4-(piperidin-4-yl)-phenyl)-7-(4-(trifluoromethyl)- phenyl)-2-naphthoic acid.
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